Ebola virus (EBOV) was the best-known and most extensively studied member of the Filoviridae family (Mononegavirales order) long before the shattering 2013–2016 West African epidemic. The virologic taxon Filoviridae was defined in 1982 and subsequently amended regularly to accommodate changes.1,2 These amendments and the unfortunate renaming of commonly used terms has made the filovirus taxonomy confusing. Today, EBOV refers to the specific member virus of the type species Zaire ebolavirus in the genus ebolavirus (Fig. 1).

The history of filoviruses largely involves human outbreaks (Fig. 1). Marburg virus (MARV) was the first filovirus to be discovered, in 1967.3 EBOV and Sudan virus (SUDV) were codiscovered in 1976 in the Democratic Republic of Congo (DRC) and South Sudan, respectively.4,5 Subsequently, two additional ebolaviruses were found to be pathogenic in humans: Taï Forest virus (TAFV) in Côte d’Ivoire in 1994 and Bundibugyo virus (BDBV) in Uganda in 2007.6,7 Reston virus (RESTV), imported into the United States from the Philippines in 1989–1990, has long been the exception, since it appears to infect humans only subclinically.8,9 Unexpectedly, it emerged in swine in the Philippines, and RESTV sequences were detected in pigs in China, raising fear about food safety.10,11 The zoonotic potential of RESTV remains unclear, and investigation of that potential is urgently needed.

More recently, genomes of new filoviruses were detected in bat and fish species. Lloviu virus (LLOV), genus cuevavirus, was sequenced from bats (Miniopterus schreibersii) in Spain and Hungary.12 Mongola virus (MLAV) sequences were found in Chinese rousettus species representing the newly proposed genus, dianlovirus.13 Bombali virus (BOMV) sequences were discovered in bats from Sierra Leone, Guinea, and Kenya; the virus is considered to be a new ebolavirus species.14 Finally, fish-derived filoviruses constitute members of two new genera, striavirus and thamnovirus.2,15 Since no isolates are available, the unknown zoonotic and pathogenic potential of these new filoviruses is a public health concern.

VIROLOGIC FEATURES

Filoviruses are enveloped, filamentous particles with a nonsegmented, negative-sense RNA genome (Fig. 1).2,16-18 The genomic RNA is encapsidated by the nucleoprotein and, together with polymerase L, polymerase cofactor virion protein (VP) 35, and transcription activator VP30, constitutes the nucleocapsid with replicase and transcriptase function. This structure interacts with the nucleocapsid-associated VP24 and is surrounded by the matrix protein VP40, the driver of particle formation. The viral spike is formed by the sole trimeric transmembrane glycoprotein and mediates viral entry; it also represents an important target for host immune responses.2,16-18 With all ebolaviruses, unlike marburgviruses, RNA editing
Ebola results in glycoprotein expression. The primary product of the glycoprotein gene is a secreted, nonstructural, soluble glycoprotein that has been implicated in antigenic subversion.16 Filoviruses replicate in the cytoplasm of their target cells.16-18 Viral particles attach to the cell surface through the binding of glycoprotein to multiple attachment factors, such as C-type lectins, and cell uptake occurs largely through macropinocytosis. Subsequently, cysteine proteases in the endosome cleave the glycoprotein, allowing it to bind to the receptor Niemann–Pick C1 and initiating membrane fusion. This process releases the genome into the cytosol, where transcription and replication by the viral replicase occur through a positive-sense antigene intermediate that functions as the template for progeny negative-sense genomes.

Figure 1. Biology, Epidemiology, and Taxonomy of Filoviruses.

In Panel A, the electron micrograph (left) includes a computer-annotated viral particle (Ebola virus, Makona strain) showing the typical filamentous shape (blue) and the core structure (yellow). The core structure (right) comprises the genomic RNA encapsidated with the viral nucleoprotein (NP) and linked with the viral transcriptase–replicase complex, which consists of virion proteins 30 and 35 (VP30 and VP35) and RNA-dependent RNA polymerase, which is further associated with VP24. The structure is surrounded by a cell-derived membrane associated with VP40 on the inside, with the glycoprotein forming spikes on the outside of the viral envelope. In Panel B, the table shows the taxonomy and some epidemiologic, ecologic, and biologic properties of the members of the Filoviridae family that are pathogenic in humans. The map shows regions in Africa with reported outbreaks. DRC denotes Democratic Republic of Congo, and RC Republic of the Congo.
positive-sense RNA transcripts are translated by host ribosomes, leading to intracellular assembly of the nucleocapsid and budding from the plasma membrane.\textsuperscript{2,16-18}

Knowledge of filoviruses is largely based on studies of EBOV and MARV, but all filoviruses are thought to follow similar principles in cell biology, with certain distinctions such as alterations in genomic structure, interferon antagonistic property, and RNA editing.\textsuperscript{2,16-18} Over the years, life-cycle modeling systems have been established for EBOV and MARV that can be safely used in biosafety level 1 and 2 laboratories.\textsuperscript{17} These systems have been instrumental in the understanding of filovirus replication and will foster therapeutic development. Future efforts should focus on studying differences between these viruses and the more recently discovered filoviruses with unknown pathogenic potential.

**Epidemiologic and Ecologic Features**

Filoviruses are zoonotic pathogens maintained in reservoir species, perhaps bats, with occasional spillover into humans and other mammals, which may serve as end, intermediate, or amplifying hosts (Fig. 2).\textsuperscript{19} This concept, however, has been established only for MARV, with isolation from *Rousettus aegyptiacus*.\textsuperscript{20} Multiple bat species
have been implicated as harboring ebolaviruses, but viral isolation has yet to be successful. This is rather uncommon and may be explained by low viral loads, low susceptibility of cell lines, or inhibitors in bat tissue. Since bats are probably hunted for food consumption in African countries, the lack of reservoir identification is a concern with respect to preventive measures.

Human pathogenic filoviruses appear to be epizootic in regions close to the African equator (Fig. 1). EBOV has caused most of the outbreaks in central and western African countries, whereas SUDV, BDBV, and the marburgviruses MARV and Ravn virus (RAVV) are more likely to cause disease in eastern Africa. RESTV is known to circulate in the Philippines and is likely to circulate elsewhere in Asia. With ongoing pathogen-detection programs, new filoviruses will probably be discovered. Evaluation of the pathogenic potential for humans will help to determine the public health threat posed by these filoviruses. Because tools for modeling and predicting outbreaks have become more sophisticated, future research should be able to focus on predicting the appearance of filoviruses in order to facilitate public health preparedness.

Epizootic and endemic viruses circulate in animals and humans, respectively, but this has not been convincingly shown for any filovirus. The frequent reemergence of EBOV in the DRC and Gabon around 2000 and that of MARV in Uganda a decade later supports the hypothesis that these filoviruses are regionally epizootic. The discovery of EBOV persistence in humans may indicate a potential to circulate temporarily in persons. Currently, however, neither EBOV nor other filoviruses can be considered to be endemic anywhere; if they were, continuing human-to-human transmission could result, a disturbing thought.

**Disease and Pathogenesis**

The clinical disease is no longer referred to as Ebola or Marburg hemorrhagic fever but rather as Ebola or Marburg virus disease (EVD or MVD), which better reflects the variable symptoms and downplays bleeding as a clinical hallmark. The incubation period is 2 to 21 days (typically, 6 to 10 days) and probably depends on the filovirus, as well as the exposure dose and route. Initially, infection is manifested as a nonspecific febrile illness characterized by malaise, fatigue, and myalgia. A few days later, gastrointestinal manifestations develop in many patients, with anorexia, nausea, vomiting, and diarrhea (Fig. 3). Fluid losses can be substantial — up to 10 liters per day. Other common signs and symptoms are dysphagia, headache, conjunctival injection, abdominal pain, arthralgia, and a maculopapular rash. Bleeding abnormalities occur in less than half of affected patients, usually manifested as bleeding from the gums, petechiae, oozing from venipuncture sites, subconjunctival hemorrhage, and blood in vomitus and stool.

Filovirus infections usually begin with the deposition of viral particles on mucous membranes and perhaps skin; occasionally infection occurs percutaneously. After uptake of the viral particles by dendritic cells and macrophages, filovirus replication potently shuts down early innate immune responses by blocking interferon production and signaling. Dissemination probably occurs through the migration of dendritic cells to lymphoid tissues and release of virus into the circulation, leading to infection of fixed macrophages in the liver, spleen, and other tissues. Infection then spreads to adjacent hepatocytes, fibroblasts, and other cells.

Disease is caused by direct effects of viral replication and host responses to infection. Viral replication leads to the formation of intracellular inclusion bodies, followed by cell lysis. Islands of necrosis appear in the liver, with a commensurate elevation in liver enzyme levels. Myositis causes muscle aches and weakness, coupled with elevation of creatine kinase and aspartate aminotransferase levels. Renal tubular cells and glomerular epithelium are affected, contributing to renal dysfunction (Fig. 3). Host responses include the production of proinflammatory cytokines and chemokines by infected dendritic cells, macrophages, and monocytes. These immune responses cause T-cell activation, which is rendered ineffective in severe or fatal cases because of T-cell exhaustion and apoptosis, followed by an impaired adaptive immune response. Proinflammatory mediators cause endothelial-cell dysfunction, followed by increased vascular permeability and fluid extravasation.
tissue factor with fibrin deposition in the spleen, lymphoid tissues, glomeruli, and renal proximal tubules. Consumption of clotting factors (from disseminated microthrombi), endothelial dysfunction, and inhibition of platelet function contribute to coagulopathy. 18,26,28-30,32 Microvascular anomalies, hypovolemia, and further fluid losses through vomiting and diarrhea ultimately lead to tissue hypoperfusion and multiorgan failure (Fig. 3).18,25,26,29,32

During the 2013–2016 EBOV epidemic, musculoskeletal pain, headache, encephalitis, and ocular problems were noted in survivors and were referred to collectively as the “post-Ebola syndrome.”33 Historically, filoviruses have been detected in multiple body fluids, including breast milk and semen, in survivors of infection. The persistence in semen, with the potential for sexual transmission more than 500 days after disease onset, is a serious concern. However, transmission this long after disease onset is very rare, with undetermined effects.34-36

**DIAGNOSIS**

Multiple techniques have been established for laboratory diagnostic methods of filovirus detection, including assays for the detection of viral genome, viral antigen, and host immune responses, even in field operations. 37,38 In the West African EBOV epidemic, on-site, high-end sequencing technology was implemented to improve outbreak response.39 In addition, simple bedside tests to detect viral antigen have become available.37,38 The most widely used technique to diagnose acute infections is a quantitative real-time polymerase-chain-reaction assay (qRT-PCR), preferably targeting two distinct genome locations to minimize false negative results due to evolving genome mutations. The qRT-PCR assay is expected to be positive in symptomatic patients, with increasing viremia in fatal cases. Since the assay may be negative early in the disease course, however, follow-up testing is warranted in patients with initially negative tests who have continuing symptoms. In the past, negative results on at least two sequential tests have been required for discharge from the treatment center. Despite improved laboratory diagnosis, individual EVD or MVD cases may still be difficult to diagnose, since clinical assessment is critical. In ill-prepared primary health care settings, diagnosis is further hampered by lack of technical capabilities. Technology transfer and training...
are still in their infancy in many African countries, but awareness of filoviruses has grown, and with simple, more reliable technologies, there is a prospect for improvement.

**PATIENT CARE**

Care of patients has traditionally had three components: supportive care to maintain or restore normal physiology, treatment of discomfort or distress, and presumptive treatment of any concurrent, undiagnosed infections (Fig. 3). The most serious derangement is hypoperfusion stemming from volume deficits due to gastrointestinal losses and vascular leakage, as well as intravascular coagulation. Thus, volume replacement through oral rehydration or intravenous crystalloid infusion is the primary intervention. With the advent of on-site biochemical testing, care now involves correcting electrolyte levels and hypoglycemia, as well as meeting nutritional needs (Fig. 3). In advanced critical care settings, additional support may be used, such as parenteral nutrition or renal-replacement therapy. Patients with headache, myalgias, and arthralgias may be offered analgesic agents. Nausea and vomiting may be relieved with the use of antiemetic agents. No less important is psychological support to help patients cope with anxiety, stress, and fear (Fig. 3).

Coinfection, whether a coincident tropical illness or an infection due to EVD or MVD, has been documented. The frequency of coinfections and the limited diagnostic options in most care settings have led to presumptive treatment with antimalarial agents and broad-spectrum antibiotics. Future advances in diagnostics should allow for more targeted antimicrobial treatment.

**INVESTIGATIONAL TREATMENT**

Efforts to develop specific treatments began shortly after the discovery of filoviruses, but when the West African Ebola epidemic struck, efficacy had been shown only in preclinical studies. Clinical trials of promising therapies were carried out during the West African outbreak, including convalescent plasma or whole blood, antibodies, small interfering RNAs, and small-molecule inhibitors (favipiravir), but none showed significant efficacy (Table 1).

In the recent Ebola outbreak in the DRC, four investigational drugs, the monoclonal-antibody cocktails ZMapp (Mapp Biopharmaceutical) and REGN-EB3 (Regeneron Pharmaceuticals), a single monoclonal antibody (MAb114, Ridgeback Biotherapeutics), and remdesivir (Gilead Sciences), a small-molecule antiviral drug, have been given to hundreds of patients under the Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) framework and in a randomized, clinical trial (Table 1). The interim results of the Pamoja Tulinde Maisha (PALM) trial suggested significantly improved survival for patients receiving MAb114 or REGN-EB3, as compared with those receiving remdesivir or ZMapp; the patients receiving ZMapp served as a control group on the basis of the results from the Partnership for Research on Ebola Virus in Liberia II (PREVAIL II) trial. Surprisingly, ZMapp performed worse in the PALM trial than in the PREVAIL II trial. The reasons remain unclear, and further analysis may be needed to shed more light on potential differences among treatment groups. Interestingly, patients receiving care and treatment earlier in the course of illness fared better than those who entered Ebola treatment units later, which had not been the case previously.

Also surprising was the fact that extremes of age, which had adversely affected outcomes in past outbreaks, were not associated with differences in outcome in the PALM trial. Patients in whom EVD developed despite previous vaccination for EBOV had much better outcomes than patients who had not been vaccinated. An analysis involving the patients who received the same therapeutics under MEURI that were provided in the PALM trial showed strikingly similar results, despite the lack of randomized treatment assignments and trial procedures.

Overall, under MEURI and in the PALM trial, antibody specificity, initially higher antibody doses, and perhaps the more favorable pharmacokinetics of human antibodies may have conferred an advantage. Remdesivir may have a delayed onset of action as compared with antibodies; however, the drug has broader applicability and, with antibodies, may represent a synergistic therapeutic approach. The preliminary results of MEURI and the PALM trial provide hope for further incremental improvements in the treatment of EVD with newer and improved investigational therapeutics or different
## Table 1. Clinical Trials of Vaccines and Antiviral Therapies for Ebola Virus Infection in Humans.

<table>
<thead>
<tr>
<th>Treatment and Study Design (Country)</th>
<th>Filovirus Species (Strain)</th>
<th>Dose</th>
<th>Regimen</th>
<th>No. of Patients and Outcome</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rVSV-ZEBOV; open-label, cluster, randomized trial of ring vaccination (Guinea)</td>
<td>Ebola (Makona)</td>
<td>$2 \times 10^7$ PFU</td>
<td>Single injection (IM)</td>
<td>5837 vaccinated; estimated efficacy, 100% (95% CI, 79.3–100.0)</td>
<td>Henao-Restrepo et al.51</td>
</tr>
<tr>
<td>rVSV-ZEBOV; randomized, placebo-controlled phase 2–3 trial (Liberia)</td>
<td>Ebola (Makona)</td>
<td>$2 \times 10^7$ PFU</td>
<td>Single injection (IM)</td>
<td>500 vaccinated (phase 3 eliminated because of decline of Ebola in Liberia)</td>
<td>Kennedy et al.52</td>
</tr>
<tr>
<td>rVSV-ZEBOV; open-label, cluster, randomized trial of ring vaccination (DRC)</td>
<td>Ebola (Kivu)</td>
<td>$2 \times 10^7$ PFU</td>
<td>Single injection (IM)</td>
<td>93,965 vaccinated; efficacy, 97.5% (95% CI, 95.8–98.5)</td>
<td>World Health Organization53</td>
</tr>
<tr>
<td>ChAd3-EBO-Z; randomized, placebo-controlled phase 2–3 trial (Liberia)</td>
<td>Ebola (Makona)</td>
<td>$2 \times 10^{11}$ particle units</td>
<td>Single injection (IM)</td>
<td>500 vaccinated (phase 3 eliminated because of decline of Ebola in Liberia)</td>
<td>Kennedy et al.52</td>
</tr>
<tr>
<td>Antiviral Therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Convalescent plasma; nonrandomized comparative study</td>
<td>Ebola (Makona)</td>
<td>Unknown</td>
<td>Two consecutive IV transfusions of 200–250 ml each</td>
<td>84 enrolled; no significant survival benefit</td>
<td>van Griensven et al.44</td>
</tr>
<tr>
<td>Convalescent blood; nonrandomized comparative study</td>
<td>Ebola (Makona)</td>
<td>Unknown</td>
<td>One IV transfusion of 450 ml given over a period of 1–4 hr</td>
<td>43 enrolled; no significant survival benefit</td>
<td>Sahr et al.45</td>
</tr>
<tr>
<td>ZMapp; phase 2–3 trial (Liberia, Sierra Leone, Guinea, United States)</td>
<td>Ebola (Makona)</td>
<td>50 mg/kg</td>
<td>One dose every 3 days (IV) for a total of three doses</td>
<td>36 enrolled, 28 survived (77.8% survival rate)</td>
<td>PREVAIL II Writing Group46</td>
</tr>
<tr>
<td>ZMapp; PALM trial (DRC)</td>
<td>Ebola (Kivu)</td>
<td>50 mg/kg</td>
<td>One dose every 3 days (IV) for a total of three doses</td>
<td>323 enrolled, 160 survived (49.5% survival rate)</td>
<td>Mulangu et al.44</td>
</tr>
<tr>
<td>MAb114; PALM trial (DRC)</td>
<td>Ebola (Kivu)</td>
<td>50 mg/kg</td>
<td>One dose (IV)</td>
<td>174 enrolled, 113 survived (64.9% survival rate)</td>
<td>Mulangu et al.44</td>
</tr>
<tr>
<td>REGN-EB3; PALM trial (DRC)</td>
<td>Ebola (Kivu)</td>
<td>150 mg/kg</td>
<td>One dose (IV)</td>
<td>155 enrolled, 103 survived (66.5% survival rate)</td>
<td>Mulangu et al.44</td>
</tr>
<tr>
<td>Remdesivir (GS-5734); double-blind, placebo-controlled, natural history trial (Liberia)</td>
<td>Ebola (Makona)</td>
<td>100 mg</td>
<td>Once daily for 5 days (IV)</td>
<td>Ongoing, with planned enrollment of 60 survivors to assess viral shedding in semen</td>
<td>Siegel et al.55</td>
</tr>
<tr>
<td>Remdesivir (GS-5734); PALM trial (DRC)</td>
<td>Ebola (Kivu)</td>
<td>200 mg loading dose; 100 mg thereafter</td>
<td>Once daily for 9–13 days (IV)</td>
<td>175 enrolled, 82 survived (46.9% survival rate)</td>
<td>Mulangu et al.44</td>
</tr>
<tr>
<td>Favipiravir (T-705); single-group trial with historical controls (Guinea)</td>
<td>Ebola (Makona)</td>
<td>6000 mg loading dose; 2400 mg thereafter</td>
<td>Two 1200-mg doses daily on days 1–9 (oral)</td>
<td>126 enrolled; no significant survival benefit</td>
<td>Sissoko et al.48</td>
</tr>
<tr>
<td>TKM-130803; single-group, phase 2 trial with historical controls (Sierra Leone)</td>
<td>Ebola (Makona)</td>
<td>0.3 mg/kg</td>
<td>Once daily for up to 7 days (IV)</td>
<td>12 enrolled; no significant survival benefit</td>
<td>Dunning et al.47</td>
</tr>
</tbody>
</table>

* CI denotes confidence interval, IM intramuscular, IV intravenous, PALM Pamoja Tulinde Maisha, and PFU plaque-forming units.
VACCINES

Vaccine development started in the 1970s with inactivated viral preparations and was followed in the 1980s and 1990s by subunit and DNA vaccine approaches. The past two decades have seen intensified use of vectored vaccines and combined approaches. Except for the EBOV DNA and adenovirus-based vaccines, none of these vaccine candidates had made it past the preclinical stage when the West African Ebola epidemic hit. This lack of preparedness for EBOV was finally corrected with several approaches that quickly moved to clinical trials (Table 1). One of the approaches is a single-shot, live-attenuated, vectored vaccine based on a recombiant vesicular stomatitis virus expressing the Zaire ebolavirus glycoprotein (rVSV-ZEBOV-GP [ERVEBO, Merck]), which was successfully tested for efficacy in a randomized trial in Guinea during the West African epidemic. The vaccine, which was approved by the European Medicines Agency and the U.S. Food and Drug Administration, has been widely administered in the DRC EBOV outbreak, with promising preliminary results (97.5% efficacy for vaccinees with an onset of illness more than 10 days after vaccination, and 88.1% for all those with EVD, regardless of the timing of illness onset). Advances in the development of other vaccines, such as the chimpanzee adenovirus 3 vaccine (ChAd3-EBO-Z, GlaxoSmithKline) and the heterologous prime–boost regimen containing the Janssen AdVac for priming, followed by Bavarian Nordic modified vaccinia Ankara (MVA-BN) technologies for boosting (Johnson & Johnson), are closing the gap between investigational and clinical use.

Since safe and immunogenic vaccine candidates are available, the question remains what strategy to choose for a specific target group. The single-shot rVSV-ZEBOV appears to be valuable when rapid immunity is needed — for example, when the objective is to target contacts of infected patients, as well as potential future contacts of current contacts, well ahead of their exposure. The prime–boost regimen may provide a more durable immune response, which takes longer to develop. Since the MVA boost contains glycoprotein sequences for multiple filoviruses and a nucleoprotein sequence for TAV, it may provide cross-protection. In general, a prime–boost approach may be preferable for persons who are at risk for exposure because of their occupation, such as health care workers, but the level of efficacy that can be achieved with the prime regimen alone is unknown. Nevertheless, the prime–boost regimen was recently added to ring vaccination in the DRC as a second approach, in the form of pop-up vaccination and targeted geographic vaccination to address security concerns and community tensions. In the future, issues such as vaccine efficacy, stability, storage, transport, and administration, as well as supply adequacy, need to be addressed for several of the vaccine products.

The protective immune responses to filovirus infections in nature are still not defined, and correlates or even mechanisms of protection are unknown. Furthermore, the protective immune response provided by vaccination may well differ among vaccine candidates and may also differ from the immune response to natural infection. The closest correlate today appears to be the total IgG response to EBOV glycoprotein.

OUTBREAK MANAGEMENT

A comprehensive response to a filovirus outbreak is a complex undertaking (Fig. 2). The principle objectives are identifying and isolating suspected cases to prevent transmission and caring for patients with EVD or MVD in order to save lives. Given the vague early clinical presentation and its similarities to common tropical illnesses, case identification requires reliable case definitions, epidemiologic linkage, and laboratory confirmation.

Another important component of the response to an outbreak is follow-up of contacts of infected patients (Fig. 2). Contacts, historically...
averaging 10 to 15 per patient, are monitored daily for 21 days, the maximum incubation period, making contact follow-up a resource-intensive effort. There is a high risk of disease transmission during traditional funerals, requiring burial practices that minimize the risk of transmission while respecting cultural values. Disinfection of the environment (e.g., at funerals and treatment centers), contaminated by infected persons and deceased bodies, is another important disease-control activity.

Complicating nearly every aspect of outbreak management is the crucial need to protect health care workers. With the small infectious inoculum, few treatments, and severe disease, a zero-tolerance practice has evolved. The iconic image of health care workers is their personal protective equipment. This equipment has many inconveniences, but none greater than heat stress, which severely limits the time safely spent in a care setting under tropical conditions.

The introduction of effective vaccines and therapeutics has great potential not only to improve outcomes for patients but also to improve outbreak control. The availability of these agents can provide a strong incentive for patients with EVD or MVD to rapidly bring themselves to the attention of surveillance systems and for persons at risk for exposure to respond to contact tracing, so long as the benefit of vaccines is clearly perceived.

Nothing may be as important as community engagement and public perception. Disease transmission stops only when the community is no longer caring for the sick in unprotected settings and burying the dead in an unsafe manner. Programs are aimed at encouraging the population to quickly alert authorities about febrile cases or unexplained deaths rather than provide care at home or engage in unprotected burials. Another important component is public education about the disease and control measures. These messages will be effective only if the community trusts the messenger. Outbreaks may occur in locations where mistrust of the national government and outside intervention is very high, as currently seen in the DRC. In environments of mistrust, the introduction of experimental countermeasures may actually bolster further mistrust. When people die in villages where vaccines were deployed and in treatment centers where experimental drugs are used, rumors of unsavory experimentation may begin to spread. Unless the ground is prepared for intervention, actions are explained, and questions answered, these new developments may be regarded as a threat.

**PERSPECTIVE ON THE FUTURE**

We have come a long way since the epidemic that devastated West Africa. We have managed to translate the fruits of laboratory research into new diagnostics, therapies, and vaccines. Now we are facing the challenges of producing and implementing these tools and moving them toward licensure, which has recently been achieved for ERVEBO. To meet these challenges, programs such as the Coalition for Epidemic Preparedness Innovations will be helpful. The next great challenge is successfully using these tools to help control outbreaks. Providing resources that are available to those most in need requires the trust of the recipient population. The current DRC outbreak shows that trust is not a given and that the value of these tools is not self-evident.

EBOV is just one of many neglected pathogens for which we are ill prepared. Can we generate the impetus and secure the funding to tackle other neglected tropical diseases? To do so would require an environment in which global strategies addressing infectious disease and health could be rapidly and effectively implemented. Efforts to achieve this goal start with surveillance and include rapid communication; unrestricted information and reagent sharing; early collaborative engagement of government, industry, and academia; rapid and coordinated responses; community education and the fostering of trust; and finally, the establishment and maintenance of local response capacities. Are we there yet? No, but we are moving slowly in the right direction.

The opinions, conclusions, and recommendations in this report are those of the authors and do not necessarily represent the official positions of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health, the University of Texas Medical Branch, or Médecins sans Frontières.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank Ryan Kissinger, NIAID Visual and Medical Arts, for help with an earlier version of the figures.
REFERENCES

42. Carroll MW, Haldenby S, Rickett NY, et al. Deep sequencing of RNA from blood and oral swab samples reveals the presence of nucleic acid from a number of pathogens in patients with acute Ebola virus disease and is consistent with bacterial translocation across the gut. mSphere 2017;2(4):e00257-17.


